Lancet Oncol:肺癌患者生活质量评估更新版(QLQ-LC29)有效

2020-05-18 MedSci MedSci原创

欧洲癌症研究和治疗组织(EORTC)生活质量调查表肺癌13(QLQ-LC13)评估了肺癌患者的生活质量(QOL),并且是为国际临床试验开发的第一个EORTC模块。自1994年发布以来,已经出现了可能对

欧洲癌症研究和治疗组织(EORTC)生活质量调查表肺癌13(QLQ-LC13)评估了肺癌患者的生活质量(QOL),并且是为国际临床试验开发的第一个EORTC模块。自1994年发布以来,已经出现了可能对QOL产生影响的重大治疗方法。这些变化要求对模块及其国际心理计量学进行更新。我们旨在研究肺癌患者中更新后的肺癌模块QLQ-LC29的量表结构和心理计量学特性。

EORTC生命质量测定量表 QLQ-C30 (V3.0)

肺癌患者生存质量测定量表(FACT-L第4版)

远期生活质量评估(Karnofsky Performance Scale,KPS)

QLQ-LC29在QLQ-LC13基础上更新而来,主要强化心理学变化的评估。

这项国际性的现场观察研究是在12个国家/地区的19家医院进行的。年龄在18岁以上、确诊为肺癌、无其他原发肿瘤、精神状态良好、有足够的语言能力理解并完成问卷的患者被纳入研究范围。患者在医院就诊时被要求填写纸质版的核心问卷EORTC QLQ-C30加QLQ-LC29,研究者选择其中一半的患者在2-4周后再次填写问卷。我们的主要目的是评估EORTC QLQ-LC29的量表结构和心理测量学特性。我们使用验证性因子分析法分析了量表结构;使用Cronbach的α值(内部一致性)和类内系数(重测信度)分析量表的可靠性;使用按Karnofsky绩效状态分层的独立t检验进行敏感性分析;采用方差分析法分析随时间变化的响应性。该研究已在ClinicalTrials.gov注册,NCT02745691。

在2016年4月12日至2018年9月26日之间,共招募了523名确诊为非小细胞肺癌(n = 442)或小细胞肺癌(n = 81)的患者。验证性因子分析提供了由五个项目维度(咳嗽,呼吸急促,恐惧进展,头发问题和手术相关症状)加15个单项症状或副作用项目组成的解决方案,χ²= 370·233,均方根近似误差= 0.075,比较拟合指数= 0.901。所有多维度标度的内部一致性的克朗巴赫(Cronbach)α都高于0.70的阈值。重测可靠性的类内系数范围的0.82和0.97之间。五个维度中的三个(呼吸急促,恐惧进展和毛发问题)显示出随时间变化的响应能力(p值<0.05),而15个单一症状项中的9个也是如此。五个维度中的四个(咳嗽,呼吸急促,恐惧进展以及与手术相关的症状)和15个单一症状项中的十个对已知的组别差异(即较低的Karnofsky表现状态与较高的Karnofsky表现状态)敏感。

结果确定了更新后的肺癌模块的心理测量特性,可以在国际临床研究中使用。

原始出处:

Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini S, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; EORTC Lung Cancer Group; European Society of Thoracic Surgeons. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.Lancet Oncol. 2020 May;21(5):723-732. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830646, encodeId=51c11830646bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 22 14:24:22 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990719, encodeId=a8661990e1972, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Mar 16 10:24:22 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865836, encodeId=5a681865836f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 26 14:24:22 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601620, encodeId=c282601620d0, content=<a href='/topic/show?id=2a61691e30d' target=_blank style='color:#2F92EE;'>#生活质量评估#</a>QLQ-LC29评估起来更复杂一点,但是更全面一点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69173, encryptionId=2a61691e30d, topicName=生活质量评估)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 12:54:40 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033788, encodeId=e4e81033e88ea, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038036, encodeId=a4651038036d1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-10-22 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830646, encodeId=51c11830646bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 22 14:24:22 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990719, encodeId=a8661990e1972, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Mar 16 10:24:22 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865836, encodeId=5a681865836f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 26 14:24:22 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601620, encodeId=c282601620d0, content=<a href='/topic/show?id=2a61691e30d' target=_blank style='color:#2F92EE;'>#生活质量评估#</a>QLQ-LC29评估起来更复杂一点,但是更全面一点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69173, encryptionId=2a61691e30d, topicName=生活质量评估)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 12:54:40 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033788, encodeId=e4e81033e88ea, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038036, encodeId=a4651038036d1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830646, encodeId=51c11830646bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 22 14:24:22 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990719, encodeId=a8661990e1972, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Mar 16 10:24:22 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865836, encodeId=5a681865836f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 26 14:24:22 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601620, encodeId=c282601620d0, content=<a href='/topic/show?id=2a61691e30d' target=_blank style='color:#2F92EE;'>#生活质量评估#</a>QLQ-LC29评估起来更复杂一点,但是更全面一点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69173, encryptionId=2a61691e30d, topicName=生活质量评估)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 12:54:40 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033788, encodeId=e4e81033e88ea, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038036, encodeId=a4651038036d1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2021-03-26 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830646, encodeId=51c11830646bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 22 14:24:22 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990719, encodeId=a8661990e1972, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Mar 16 10:24:22 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865836, encodeId=5a681865836f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 26 14:24:22 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601620, encodeId=c282601620d0, content=<a href='/topic/show?id=2a61691e30d' target=_blank style='color:#2F92EE;'>#生活质量评估#</a>QLQ-LC29评估起来更复杂一点,但是更全面一点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69173, encryptionId=2a61691e30d, topicName=生活质量评估)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 12:54:40 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033788, encodeId=e4e81033e88ea, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038036, encodeId=a4651038036d1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-06-06 lovetcm

    #生活质量评估#QLQ-LC29评估起来更复杂一点,但是更全面一点。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1830646, encodeId=51c11830646bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 22 14:24:22 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990719, encodeId=a8661990e1972, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Mar 16 10:24:22 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865836, encodeId=5a681865836f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 26 14:24:22 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601620, encodeId=c282601620d0, content=<a href='/topic/show?id=2a61691e30d' target=_blank style='color:#2F92EE;'>#生活质量评估#</a>QLQ-LC29评估起来更复杂一点,但是更全面一点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69173, encryptionId=2a61691e30d, topicName=生活质量评估)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 12:54:40 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033788, encodeId=e4e81033e88ea, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038036, encodeId=a4651038036d1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-18 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1830646, encodeId=51c11830646bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 22 14:24:22 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990719, encodeId=a8661990e1972, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Mar 16 10:24:22 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865836, encodeId=5a681865836f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 26 14:24:22 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601620, encodeId=c282601620d0, content=<a href='/topic/show?id=2a61691e30d' target=_blank style='color:#2F92EE;'>#生活质量评估#</a>QLQ-LC29评估起来更复杂一点,但是更全面一点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69173, encryptionId=2a61691e30d, topicName=生活质量评估)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 12:54:40 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033788, encodeId=e4e81033e88ea, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038036, encodeId=a4651038036d1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon May 18 10:24:22 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-18 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

AACR 2020:肿瘤浸润淋巴细胞(TIL)疗法挑战PD-1耐药性肺癌

TIL疗法治疗PD-1耐药性非小细胞肺癌患者的1期结果积极。其实在去年的ASCO年会上,Iovance Biotherapeutics公司就公布了其创新细胞疗法LN-145和lifleucel在治疗宫

治疗特定肺癌患者,武田EGFR抑制剂获突破性疗法认定

今日,武田(Takeda)公司宣布,美国FDA已授予其在研EGFR/HER2抑制剂mobocertinib(TAK-788)突破性疗法认定,用于治疗携带EGFR外显子20插入(exon 20 inse

Chest:非小细胞肺癌按农村、分期进行分层的治疗方式和生存率

在患者和医院水平存在与农村相关的治疗和生存率差异,但医院水平的差异更大。

Sci Rep:氧化磷酸化基因高表达可预测肺部鳞状细胞癌的生存率改善

这些数据为旨在表征肿瘤线粒体活性与肿瘤免疫微环境之间相互作用的研究提供了有力支持。

肺癌高居恶性肿瘤死亡率首位,看湘雅医院如何快速确诊

众所周知,肺癌连续多年占据我国恶性肿瘤发病率和死亡率首位,严重威胁着人类的健康。肿瘤的确诊需要多科室的协作,其中,由病理科承担的病理诊断是肿瘤疾病确诊的金标准,因此病理科在肿瘤确诊的过程中起着至关重要

Chest:非小细胞肺癌支气管超声引导下经支气管针吸活检术检测PD-L1

EBUS-TBNA提供的样本足以进行PD-L1检测,并且晚期患者和存在脑转移与PD-L1表达升高相关。